Abstract
INTRODUCTION: pain is a very common symptom in patients with Multiple Sclerosis, 42 to 65% of patients present it. As the severe symptom, pain in these patients is between 8 to 32%. All central pain syndromes are presented by injury or dysfunction of the central nervous system, causing severe disability and deterioration in the quality of life of patients.
OBJECTIVE: to assess the analgesic effectiveness of pharmacotherapies in central pain in patients with Multiple Sclerosis (MS), in order to provide evidence-based recommendations for clinical practice
METHODOLOGY: search strategy: we identified randomized trials of pharmacotherapies treatment of central pain in patients with Multiple Sclerosis, MEDLINE (1965-September 2007), EMBASE (2000 to 2007), and Lilacs (1990-2007). Additional reports were identified from the reference lists of retrieved articles. Date of the most recent search: September 2007. Selection criteria: clinical studies randomized controlled double blind, duration of treatment equal to 1 or more days, compared to placebo or one or more pharmacological therapies in patients with Multiple Sclerosis, with a subjective evaluation of pain as primary or secondary results. Data collection and analysis: seven studies were considered eligible, of whom 4 are cannabinoids studies, a study with morphine IV, another with Lidocaina and Mexiletina and finally a combination of Lofepramina, Vitamin B12 and phenylalanine.
RESULTS: the inadequate quality of available studies warrants further investigation. Intervention trials with pharmacological therapy (cannabinoids, morphine, lidocaine, mexiletine, lofepramina combination of Vitamin B12, L-phenylalanine) or other intervention undoubtedly require adequate sample sizes, designs, randomized controlled parallel group and clinically relevant outcome measures reliable, and sensitive.
But in studies with cannabinoids, it is observed that it is better than placebo, and that in terms of clinical relevance, impact on patient functioning and quality of life related to health has a beneficial effect.
CONCLUSIONS: more studies are needed based on clinical evidence, which yield the best results of non-pharmacological or pharmacological treatments, with high efficiency and effectiveness with fewer side effects, which prevent the abandonment of treatment by patients. And to ensure a better quality of life and performance of their daily life activities.
Although the evidence that cannabis and single cannabinoids are effective in pain management, are not conclusive, this is enough to order clinical trials of cannabinoids that may provide more clinical information about the effectiveness and presentation of adverse effects.
The poor quality of the available studies warranted further investigations.
References
Neumann H, Cavalie A, Jenne DE, Wekerle H. Induction of MHC class I genes in neurons. Science 1995; 269:549-552.
Maehler J, Schroder HD, Klareskog L, Olsson T, Kristensson K. Axotomy induces MHC class I antigen expression on rat nerve cells. Neurosci Lett 1988; 92:8-13.
Kurztke JF. Epìdemiology of multiple sclerosis. En: Vinken PJ, Bruyen GW, Klawans HL,eds. Handbook of Clinical
Neurology, vol 3 (Elsevier: Amsterdam 1985) 259-28.
Sadovnick Ad, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20:17-29.
Zilber N, Kahana E. Pitfalls in multiple sclerosis Epidemiology. En: Frontiers in Multiple Sclerosis. Clinical research and therapy. Edited O.Abramsky, H Ovadia. (Martin Dunitz 1997):22-28.
Oesterberg A, Boivie J, Thuomas K. Central Pain in Multiple Sclerosis, prevalence and clinical characteristics, European Journal of Pain 2005:9;05 531-542.
Moulin DE, Foley KM, Ebers GC. Pain Syndromes in multiple sclerosis. Neurology 1988; 38: 1830 - 34.
Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984, 41: 1270 -72.
Shrager P, Novakovic SD. Control of myelination, axonal growth, and synapse formation in spinal cord explants by ion channels and electrical activity. Brain Res Dev Brain Res 1995; 88:68-78.
Kalman S, et al. Morphine responsiveness in a group of well? defined multiple sclerosis patients: A Study with i.v. Morphine. European of Journal of Pain 2002; 6:69 -80.
Wade D, Makela P, Robson P, House H, Bateman C. Does Cannabis ? based extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo controlled study on 160 patients, Multiple Sclerosis; 2004; 10: 434 - 441.
Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. Journal of Neurological Sciences 1999: 162 - 168.
Rog D, et al. Randomized, controlled trial of cannabis- based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812 - 819.
Svendsen K, Jensen T, Bach F. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. British Medical Journal 2004;329: 253.
Loder, et al. Treatment of multiple sclerosis with lofepramine, L phenylalanine and vitamin b12: mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. Medical Hypotheses 2002; 59: 594 - 602.
Zacijek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS Study): multicentre randomized placebo controlled trial. Lancet 2003; 362: 1517 - 1526.
Notcutt W, Price M, Miller R, et al. Initial experiences with medical extracts of cannabis for chronic pain: results from 34 ?n de 1? studies. Anaesthesia 2004; 59: 440-452.
Wade DT, Robson P, House H, et al. A preliminary controlled study to determine wether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation 2003; 17: 21-29.
Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-1407.
Greenberg HS, Werness SA, Pugh JE, et al. Short-terms effects of marijuana on balance in patients with multiple sclerosis and normal volunteers. Clinical Pharmacological and therapeutics 1994; 55: 324-328.
Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur
Neurol 1997; 38: 44-8.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.